Updated
Edgewise TherapeuticsEWTX · Healthcare
$45.04+15.87%
Market cap$4.9B
IndustryBiotechnology
Edgewise Therapeutics (EWTX) Superinvestor holders
11 of the superinvestors we track hold Edgewise Therapeutics (EWTX) in their latest 13F filings, $45M in total.
Summary
The largest holder is Artisan Partners, with $23M, 0.0% of the portfolio.
In their latest quarter: 3 opened a new position, 4 added, 3 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Artisan Partners | Trimmed | 574,925 | $23M | 0.0% | Q2 2026 |
| David Shaw D. E. Shaw & Co. |
Added | 189,115 | $8M | 0.0% | Q2 2026 |
| Steve Cohen Point72 Asset Management |
New position | 117,262 | $5M | 0.0% | Q2 2026 |
| Paul Tudor Jones Tudor Investment Corp |
Added | 56,934 | $2M | 0.0% | Q2 2026 |
| Two Sigma Two Sigma Investments |
Trimmed | 49,548 | $2M | 0.0% | Q2 2026 |
| Ensign Peak Ensign Peak Advisors |
New position | 40,379 | $2M | 0.0% | Q2 2026 |
| Alan Howard Brevan Howard |
New position | 26,566 | $1M | 0.0% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Added | 18,456 | $749,869 | 0.0% | Q2 2026 |
| Acadian Acadian Asset Management |
Added | 11,995 | $486,000 | 0.0% | Q3 2026 |
| Didric Cederholm Lion Point Capital |
Held | 9,100 | $369,733 | 1.8% | Q2 2026 |
| Paul Marshall Marshall Wace |
Trimmed | 6,100 | $247,843 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 11 |
| Q1 2026 | 8 |
| Q4 2025 | 8 |
| Q3 2025 | 4 |
| Q2 2025 | 6 |
| Q1 2025 | 9 |
| Q4 2024 | 13 |
| Q3 2024 | 13 |
Questions about Edgewise Therapeutics
Which superinvestors own Edgewise Therapeutics?
11 of the superinvestors we track hold Edgewise Therapeutics (EWTX) in their latest 13F filings, $45M in total. Artisan Partners, David Shaw, Steve Cohen, Paul Tudor Jones, Two Sigma, Ensign Peak.
Who is the largest superinvestor holder of EWTX?
The largest holder is Artisan Partners, with $23M, 0.0% of the portfolio.
From Edgewise Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.